$55.3
+0.11
(+0.2%)▲
2.84%
Downside
Day's Volatility :3.69%
Upside
0.88%
66.18%
Downside
52 Weeks Volatility :66.66%
Upside
1.41%
Period | Arcellx, Inc. | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 49.66% | 0.3% | 0.0% |
6 Months | 34.81% | 1.7% | 0.0% |
1 Year | 191.21% | -4.0% | -2.4% |
3 Years | 229.17% | 17.2% | -6.5% |
Market Capitalization | 2.7B |
Book Value | $5.47 |
Dividend Share | 0.0 |
Dividend Yield | 0.0% |
Earnings Per Share (EPS) | -2.65 |
Wall Street Target Price | 60.09 |
Profit Margin | -274.59% |
Operating Margin TTM | -299.94% |
Return On Assets TTM | -19.03% |
Return On Equity TTM | -51.56% |
Revenue TTM | 47.2M |
Revenue Per Share TTM | 1.01 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -143.1M |
Diluted Eps TTM | -2.65 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -2.51 |
EPS Estimate Next Year | -2.22 |
EPS Estimate Current Quarter | -0.54 |
EPS Estimate Next Quarter | -0.68 |
What analysts predicted
Upside of 8.66%
Sell
Neutral
Buy
Arcellx, Inc. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Arcellx, Inc. | 22.08% | 34.81% | 191.21% | 229.17% | 229.17% |
![]() Moderna, Inc. | 8.62% | -38.31% | -54.89% | -50.93% | 320.86% |
![]() Regeneron Pharmaceuticals, Inc. | -1.38% | 9.73% | 9.82% | 65.7% | 115.07% |
![]() Novo Nordisk A/s | -1.43% | 23.95% | 58.41% | 192.13% | 336.59% |
![]() Seagen, Inc. | 0.74% | 10.42% | 83.05% | 20.41% | 247.89% |
![]() Vertex Pharmaceuticals Incorporated | -8.19% | 7.19% | 13.58% | 55.97% | 97.18% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Arcellx, Inc. | NA | NA | NA | -2.51 | -0.52 | -0.19 | 0.0 | 5.47 |
![]() Moderna, Inc. | 24.73 | NA | 0.0 | -12.72 | -0.22 | -0.07 | 0.0 | 35.32 |
![]() Regeneron Pharmaceuticals, Inc. | 23.18 | 23.18 | 1.75 | 42.5 | 0.17 | 0.09 | 0.01 | 234.47 |
![]() Novo Nordisk A/s | 41.18 | 41.18 | 4.02 | 2.67 | 0.89 | 0.22 | 0.01 | 20.77 |
![]() Seagen, Inc. | NA | NA | 18.53 | -4.16 | -0.28 | -0.13 | 0.03 | 13.52 |
![]() Vertex Pharmaceuticals Incorporated | 26.38 | 26.38 | 0.5 | 15.04 | 0.23 | 0.14 | 0.0 | 64.05 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Arcellx, Inc. | Buy | $2.7B | 229.17% | NA | -274.59% |
![]() Moderna, Inc. | Buy | $30.4B | 320.86% | 24.73 | -38.0% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $88.5B | 115.07% | 23.18 | 30.47% |
![]() Novo Nordisk A/s | Buy | $459.0B | 336.59% | 41.18 | 35.11% |
![]() Seagen, Inc. | Hold | $40.2B | 247.89% | NA | -32.61% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $90.5B | 97.18% | 26.38 | 35.94% |
FMR Inc
Perceptive Advisors LLC
SR ONE CAPITAL MANAGEMENT, LP
NEA Management Company, LLC
Paradigm Biocapital Advisors LP
Suvretta Capital Management, LLC
Arcellx, Inc.’s price-to-earnings ratio stands at None
Read MoreArcellx Inc. is a clinical-stage biotechnology company. The Company is focused developing controllable cell therapies for the treatment of patients with cancer and other incurable diseases.
Organization | Arcellx, Inc. |
Employees | 98 |
CEO | Mr. Rami Elghandour |
Industry | Healthcare |